Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
Pulse Biosciences, Inc. (PLSE) announced agreements with the Clayman Thyroid Center at the Hospital for Endocrine Surgery and its affiliates, forming a commercial and clinical partnership around the nPulse Vybrance Percutaneous Electrode System.
Commercial use has begun, with the center treating patients as part of Pulse Biosciences’ controlled market development strategy. In the clinical collaboration, the parties will collect real-world patient outcomes and conduct formal studies evaluating nsPFA energy for benign thyroid nodules. Pulse Biosciences expects the work to add meaningfully to the evidence supporting Vybrance.
Pulse Biosciences, Inc. reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF study across 15 clinical sites, three months ahead of its original 9-month timeline. The prospective, multicenter, non-randomized IDE pivotal investigation evaluates the safety and effectiveness of the nPulse Cardiac Catheter System in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation.
Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation. The company plans to provide study updates as patients complete follow-up and expects to present pivotal data at a future medical society conference.
PULSE BIOSCIENCES, INC. (PLSE) entered into a new at-the-market equity distribution agreement to offer up to $85,000,000 of common stock through Mizuho Securities USA LLC. Mizuho will act as sales agent and may sell shares from time to time in transactions deemed to be “at the market” offerings under Rule 415, including ordinary broker transactions on The Nasdaq Capital Market, block trades and other permitted negotiated transactions. The company will pay Mizuho a commission of up to 3.0% of the gross sales price of any shares sold and will reimburse certain expenses. The shares will be offered under an effective Form S-3 shelf registration and an accompanying prospectus supplement filed on September 15, 2026. Separately, on September 14, 2026, the company terminated its prior at-the-market program under the TD Cowen Distribution Agreement, under which $1.0 million of capacity remained unused at termination.
Pulse Biosciences, Inc. (PLSE) filed a prospectus supplement for a new at-the-market equity program, allowing sales of up to $85,000,000 of common stock from time to time through Mizuho Securities USA LLC as sales agent under its $200,000,000 shelf registration. The company expects to complete its prior August 2026 ATM program before using this new facility. Shares outstanding were 70,799,962 as of June 30, 2026, and would be up to 72,367,938 if 1,567,976 shares were sold at $54.21 per share.
Net proceeds, if any, are intended for general corporate purposes, primarily to fund clinical evaluations and IDE studies of the nPulse Cardiac Catheter and nPulse Cardiac Clamp in the U.S. and Europe, regulatory submissions, and further development and early commercialization of the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and other applications. The filing highlights that investors may experience substantial dilution: at an assumed price of $54.21, as-adjusted net tangible book value would be $2.47 per share, implying immediate dilution of $51.74 to new investors, while existing holders would see a $1.11 per-share increase in net tangible book value.
PULSE BIOSCIENCES, INC. (PLSE) reported that it has completed patient enrollment in its PRECISE-BTN clinical study evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for treating symptomatic benign thyroid nodules. The study was expanded from an original 50-patient design to 100 patients across three U.S. clinical sites.
All 100 patients were enrolled in approximately 12 months at Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine. The first patient has completed the final 12-month follow-up visit. Patients are followed at 1, 3, 6, and 12 months, with endpoints including safety, nodule volume reduction, symptom relief, hormone normalization, and quality-of-life improvements.
PULSE BIOSCIENCES, INC. (PLSE) Chief Operating Officer Liane Rae Teplitsky reported open-market purchases of company common stock. On August 31, 2026, she purchased 1,024 shares at a weighted average price of about $48.80 per share, in trades executed between $48.76 and $48.80. On September 1, 2026, she purchased an additional 1,001 shares at $49.95 per share. All trades were made in an open trading window under the company’s Insider Trading Policy, and no Rule 10b5-1 trading plan is reported.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky purchased common stock in two open-market transactions. On August 26, 2026 she bought 1,036 shares at $48.235 per share, and on August 28, 2026 she bought 1,034 shares at $48.35 per share, during an open trading window under the company’s Insider Trading Policy. Fractional-share amounts were rounded down, and same-price trades on each day were aggregated into single reported lines.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky received equity awards on August 8, 2026. She was granted 200,000 Restricted Stock Units, each representing one share of common stock, and 700,000 stock options with an exercise price of $19.06 per share. The RSUs vest upon performance-based criteria set by the board. Two sevenths of the option shares vest in equal installments on each of the first four anniversaries of the grant date, with the remainder vesting upon achieving performance targets tied to company market capitalization and GAAP product revenue, subject to continued service.
PULSE BIOSCIENCES, INC. (PLSE) filed an initial ownership report for Liane Rae Teplitsky, who serves as Chief Operating Officer. The Form 3 does not list any reportable holdings or transactions and includes a power of attorney as an exhibit authorizing certain filings on her behalf.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Financial Officer Jon Skinner received a grant of stock options for 300,000 shares of common stock on February 3, 2025. The options have an exercise price of $20.93 per share and expire on February 3, 2035. Half of the options vest in equal installments over four years, and the remaining half vest in tranches tied to performance goals based on the company’s market capitalization between $2 billion and $5 billion and GAAP revenue targets between $48 million and $175 million, subject to his continued service.